Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
January 26, 2017 at 09:54 pm IST
Opiant Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the 2mg formulation of NARCAN Nasal Spray for opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. NARCAN is partnered with and marketed in the U.S. by privately-held Adapt Pharma.